<DOC>
	<DOCNO>NCT01010087</DOCNO>
	<brief_summary>Primary Objectives : The primary objective trial compare antiviral efficacy 10 day course standard ( 75 mg bid ) high-dose ( 225 mg bid ) oseltamivir ( equivalent dose mild-moderate renal failure ) treatment severe influenza infection . The hypothesis high dose oseltamivir increase proportion patient negative reverse transcriptase ( RT ) -PCR detection influenza viral RNA ( viral culture , select site ) Day 5 post-treatment . An important secondary objective trial , reflect main clinical objective , determine difference number ventilator day standard-dose high-dose group</brief_summary>
	<brief_title>Trial Comparing High Versus Standard Dose Oseltamivir Severe Influenza Infection ICU</brief_title>
	<detailed_description>Primary Objectives : The primary objective trial compare antiviral efficacy 10 day course standard ( 75 mg bid ) high-dose ( 225 mg bid ) oseltamivir ( equivalent dose mild-moderate renal failure ) treatment severe influenza infection . The hypothesis high dose oseltamivir increase proportion patient negative reverse transcriptase ( RT ) -PCR detection influenza viral RNA ( viral culture , select site ) Day 5 post-treatment . An important secondary objective trial , reflect main clinical objective , determine difference number ventilator day standard-dose high-dose group . Secondary Objectives : - Laboratory objective : 1 . Assess viral RNA load clearance nasopharyngeal tracheal aspirate ( intubate ) oropharyngeal ( non-intubated ) sample RT-PCR day 1 , 3 , 5 , 7 , 10 , 14 28 day 2 . Determine viral clearance culture nasopharyngeal tracheal aspirate ( intubate ) oropharyngeal ( non-intubated ) sample day 1 , 3 , 5 , 7 , 10 , 14 28 day select hospital site culture capability 3 . Assess pharmacokinetics oseltamivir carboxylate phosphate Day 3 suspect H1N1 patient respiratory distress and/or critical illness require ICU care 4 . Characterize inflammatory cytokine response Day 1-3 , 5 , 7 , 10 , 14 , 21 28 day severe influenza stratify standard-dose versus high-dose oseltamivir therapy . 5 . Assess leukocyte gene expression day 1 , 3 , 5 , 10 21 day use high throughput RNA assessment technique 6 . Examine urine biomarkers disease severe disease - Clinical Safety Objectives : 1 . Determine difference number ventilator day standard-dose high-dose group 2 . Determine tolerability high-dose versus standard-dose oseltamivir assess number serious , atypical drug-related adverse event possibly probably related oseltamivir 3 . Assess secondary efficacy variable include survival duration , hospital free day day 60 , ICU free day day 60 , shock ( ie vasopressor ) renal failure free ( ie require hemodialysis ; ultrafiltration acceptable ) day day 28 relation high vs standard dose oseltamivir therapy 4 . Assess 60 day mechanical ventilation ICU-free day stay relation high v standard dose oseltamivir therapy 5 . Determine clinical criterion use clinician elect continue re-initiate oseltamivir therapy beyond 10 study day treatment course Tertiary Objectives : Exploratory Analyses - Laboratory Objectives : 1 . Assess relationship pharmacokinetic variable day 3 measure viral clearance 2 . Assess frequency genetic basis antiviral resistance oseltamivir therapy 3 . Determine possible host genetic factor include HLA type predispose severe influenza - Clinical Safety Objectives : 1 . Determine difference development persistence adverse clinical sign ( fever , heart rate , hypotension ) , requirement duration organ support ( supplemental oxygen , vasopressor/inotropes , continuous renal replacement therapy ) occurrence resolution organ failure Sequential Organ Failure Assessment ( SOFA ) score day 7 , 10 , 14 28 consequence high-dose versus standard-dose oseltamivir 2 . Determine impact oseltamivir dose frequency progression mechanical ventilation among non-ventilated patient</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Oseltamivir</mesh_term>
	<criteria>1 . Patients age 12 old 45 kg 2 . Suspected confirmed influenza ( Appendix A ) 3 . Requirement ICU admission due respiratory distress critical illness define one : 1 . Inspired oxygen need &gt; 50 % least 4 hour ( For FiO2 nonintubated patient see Appendix B ) 2. mechanical ventilation 3 . Patient receive inotrope vasopressor 4 . Negative bHCG test negative bedside urine test pending confirmatory bHCG test pregnancy woman childbearing age ( 1260 year age ) allow study entry 1 . Inability obtain consent 2 . Patients receive two dos 150 mg high oseltamivir 36 hour study entry 3 . Patients receive 3 dos 75 mg oseltamivir immediately 36 hour study entry 4 . Age le 12 year , age &lt; 16 weight less 45 kg 5 . Unlikely absorb enteral study drug ( e.g . patient partial complete mechanical bowel obstruction , intestinal ischemia , infarction , short bowel syndrome ) 6 . Known allergy hypersensitivity oseltamivir 7 . Pregnancy breast feed 8 . Previous enrollment current study 9 . Concurrent involvement RCT examine antiviral agent include neuraminidase inhibitor , interferona and/or ribavirin 10 . Chronic renal failure require chronic hemodialysis 11 . Severe chronic liver disease ( ChildPugh Score 1115 ) 12 . Anticipated death within 24 hour judge attend physician local PI 13 . Patient carry `` intubate '' order ( `` CPR '' `` defibrillate '' `` chest compression '' order alone allow )</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>patient admit ICU</keyword>
</DOC>